drugset / Trial / NCT02909153
Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
RandomizedCrossoverOpen-labelTreatment
Summary
The main purpose is to determine the pharmacokinetic (PK) profile, maximum concentration (Cmax) and Area Under the Concentration Time Curve (AUC0-t) of Triferic iron administered intraperitoneally in patients with chronic kidney disease on peritoneal dialysis (CKD-5 PD). It is an open label, dose escalation study.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triferic | Other / unclassified | 5 unknown | Other |
| Subject | Triferic | Other / unclassified | 6.6 mg | Other |
| Subject | Triferic | Other / unclassified | 12.5 unknown | Other |
| Subject | Triferic | Other / unclassified | 20 unknown | Other |